Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 47c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $215.98 +3.92%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.71, $0.47 worse than the analyst estimate of $6.18. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.600-4.750 billion, versus the consensus of $4.512 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
